Antileukemic effect of interleukin-2-transduced murine bone marrow after autologous transplantation

Biology of Blood and Marrow Transplantation

Volumn 5, Issue 3, 1999, Pages 144-154

  Tam, Ying K ^a   Klingemann, Hans G ^b  

^a RUSH CANCER INSTITUTE   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Antileukemic; Autologous transplantation; Gene therapy; GVL; Interleukin 2

Indexed keywords

INTERLEUKIN 2;

ANIMAL; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL STRAIN 3T3; GENETICS; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIESIS; MALE; METHODOLOGY; MOUSE; RADIATION CHIMERA; RADIATION EXPOSURE; RETROVIRUS; VIROLOGY; VIRUS CELL TRANSFORMATION;

3T3 CELLS; ANIMALS; BONE MARROW; BONE MARROW TRANSPLANTATION; CELL TRANSFORMATION, VIRAL; GRAFT VS TUMOR EFFECT; HEMATOPOIESIS; INTERLEUKIN-2; MALE; MICE; MICE, INBRED C57BL; RADIATION CHIMERA; RETROVIRIDAE; TRANSPLANTATION, AUTOLOGOUS;

EID: 0032603533     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.1999.v5.pm10392960     Document Type: Article

References (50)

1. McGlave PB, Haake RJ, Bostrom BC, Brunning R, Hurd DD, Kim TH, Nesbit ME, Vercellotti GM, Weisdorf D, Woods WG, Ramsay NKC, Kersey, JH: Allogeneic bone marrow transplantation for acute nonlymphocytic leukemia in first remission. Blood 72:1512, 1988.
2. Geller RB, Saral R, Piantadosi S, Zahurak M, Vogelsang GB, Wingard JR, Ambinder RF, Beschorner WB, Braine HG, Burns WH, Hess AD, Jones RJ, May WS, Rowley SD, Wagner JE, Yeager AM, Santos GW: Allogeneic bone marrow transplantation after high dose busulfan and cyclophosphamide in patients with acute myelogenous leukemia. Blood 73:2209, 1989.
3. Rees JK, Gray RG, Swirsky D, Hayhoe FG: Principal results of the Medical Research Council's 8th acute myeloid leukemia trial. Lancet 2:1236, 1986.
4. Phillips GL, Reece DE, Shepherd JD, Barnett MJ, Brown RA, Frei-Lahr DA, Klingemann HG, Bolwell BJ, Spinelli JJ, Herzig RH, Herzig GP: High-dose cytarabin and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia. Blood 77:1429, 1991.
5. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, Anasetti C, Beatty P, Bensinger WI, Doney K, Hill RS, McDonald GB, Martin P, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Starb R, Hansen JA, Thomas ED: Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: randomized trial of two irradiation regimens. Blood 76:1867, 1990.
6. Martin PJ, Hansen JA, Buckner CD, Sanders JE, Deeg HJ, Stewart P, Appelbaum FR, Clift R, Fefer A, Witherspoon RP, Kennedy MS, Sullivan KM, Fluornoy N, Storb R, Thomas ED: Effects of in vitro depletion of T-cells in HLA-identical allogeneic marrow grafts. Blood 66:664, 1985.
7. Maraninchi D, Gluckman E, Blaise D, Guyotat D, Rio B, Pico JL, Leblond V, Michallet M, Dreyfus F, Ifrab N, Bordigoni A: Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard risk leukemias. Lancet 2:175, 1987.
8. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD: Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 71:723, 1988.
9. Sanz MA, de la Rubia J, Sanz GF, Martin G, Martinez J, Jarque I, Sempere A, Gomis F, Senent L, Soler MI: Busulfan plus cyclophosphamide followed by autologous stem-cell transplantation for patients with acute myeloblastic leukemia in first remission: a report from a single institution. J Clin Oncol 11:1661, 1993.
10. McMillan AK, Goldstone AH, Linch DC, Gribben JG, Patterson KG, Richards JD, Franklin I, Boughton BJ, Milligan DW, Leyland MM, Hutchison RM, Newland AC: High dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia. Blood 76:480, 1990.
11. Yeager A, Quaskey S, Mellis ED, Santos GW: Autologous bone marrow transplantation (ABMT) with chemopurged marrow for acute myeloid leukemia (AML): analysis of factors predictive of outcome. Blood 80(Suppl 1):65a, 1992.
12. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990.
13. Brenner M, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN: Gene-marking to trace origin of relapse after bone autologous bone marrow transplantation. Lancet 341:85, 1993.
14. Weiden PL Flournoy N, Thomas ED, Prentice R, Fefer A, Bruckner CD, Starb R: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic grafts. N Engl J Med 300:1068, 1979.
15. Gale RP, Champlin R: How does bone marrow transplantation cure leukemia? Lancet 2:28, 1984.
16. Roy J, Blaise D, Ochs L, Weisdorf D: The tissue expression of cytokines in human acute cutaneous graft-versus-host disease. Blood (Suppl 1) 82:422a, 1993.
17. Heslop HE, Gottlieb DJ, Bianchi ACM, Meager A, Prentice HG, Mebta AB, Hoffbrand AV, Brenner MK: In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transplantation. Blood 74:1374, 1989.
18. Klingemann HG, Grigg AP, Wilkei-Boyd K, Barnett MJ, Eaves AC, Reece DE, Shepherd JD, Phillips GL: Treatment with recombinant interferon (a-2b) early after bone marrow transplantation in patients at high risk for relapse. Blood 78:3306, 1991.
19. Higuichi CM, Thompson JA, Peterson FB, Buckner CD, Fefer, A: Toxicity and immunomodulatory effects of IL-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 77:2561, 1991.
20. Soiffer RJ, Murray C, Cochran K, Cameron C, Wang E, Schow PW, Daley JF, Ritz J: Clinical and immunological effects of prolonged infusion of low-dose recombinant IL-2 after autologous and T-cell depleted allogeneic bone marrow transplantation. Blood 79:517, 1992.
21. Korngold R, Leighton C, Mauser T: Graft-versus-myeloid leukemia responses following syngeneic and allogeneic bone marrow transplantation. Transplantation 58:278, 1994.
22. Dexter TM, Allen TD, Lajtha LG: Conditions controlling the proliferation of hemopoietic stem cells in vitro. J Cell Physiol 91:335, 1977.
23. Coulombel L, Eaves AC, Eaves CJ: Enzymatic treatment of long-term human marrow cultures reveals the preferential location of primitive hemopoietic progenitors in the adherent layer. Blood 62:291, 1983.
24. Agab R, Malloy B, Kerner M, Mazumder A: Generation and characterization of IL2-activated bone marrow cells as a potent graft vs tumor effector in transplantation. J Immunol 143:3092, 1989.
25. Beaujean F, Bernaudin F, Kuentz M, Lemerle S, Cordonnier C, Le Forestier C, Reinert P, Duedari N, Brandely M, Vernant JP: Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia. Bone Marrow Transplant, 15:691, 1995.
26. Soiffer RJ, Murray C, Gonin R, Ritz J: Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 84:964, 1994.
27. Mazumder A: Experimental evidence of interleukin-2 activity in bone marrow transplantation. Cancer J Sci Am 3(Suppl 1):S37, 1997.
28. Charak BS, Brynes RK, Groshen S, Chen SC, Mazumder A: Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice. Blood 76:2187, 1990.
29. Klingemann HG, Eaves CJ, Barnett MK, Eaves AC, Hogge DE, Nantel SH, Reece E, Shepard JD, Sutherland HJ, Phillips GL: Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 14:389, 1994.
30. Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, Schow P, Ross ME, Klump TR, Soiffer RJ, et al: Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 91:123, 1993.
31. Kuhr T, Dougherty GJ, Klingemann HG: Transfer of the tumor necrosis factor a gene into hematopoietic progenitor cells as a model for site specific cytokine delivery after marrow transplantation. Blood 84:2966, 1994.
32. Hwu P, Yannelli J, Kriegler M, Anderson WF; Perez C, Chiang Y, Schwarz S, Cowherd R, Delgado C, Mule J, Rosenberg SA: Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-alpha cDNA for the gene therapy of cancer in humans. J Immunol 150:4104, 1993.
33. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E: The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol 152:2324, 1994.
34. Hawley RG, Fong AZC, Burns BF, Hawley TS: Transplantable myeloproliferative disease induced in mice by an interleukin-6 retrovirus. J Exp Med 176:1149, 1992.
35. Hawley RG, Fong AZC, Lu M, Hawley TS: The Hox11 homeobox-containing gene of human leukemia immortalizes murine hematopoietic precursors. Oncogene 9:1, 1994.
36. Carron JA, Cawley JC: IL-2 abolishes fibroblast proliferation in long-term bone marrow cultures by inhibition of an accessory cell. Br J Haematol 79:377, 1991.
37. Ettinghausen SE, Moore JG, White DE, Platanias L, Young NS, Rosenberg SA: Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 69:1654, 1987.
38. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson GG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889, 1987.
39. Naldini A, Fleishmann WR Jr, Ballas, ZK, Klimpel KD, Klimpel GR: Interleukin 2 inhibits in vitro granulocyte-macrophage colony formation. J Immunol 139:1880, 1987.
40. Cerique M, Pisa P, Tsai L, Hanson M: Effects of interleukin-2 and interleukin-2-activated cells on in vitro myelopoiesis. Clin Exp Immunol 81:459, 1990.
41. Gibson FM, Malokovska V, Myint AA, Meager A, Gordon-Smith EC: Mechanism of suppression of normal hematopoietic activity by lymphokine-activated killer cells and their products. Exp Hematol 19:659, 1991.
42. Ho SP, Hafez GR, Ershler WB: The effects of interleukin-2 on bone marrow engraftment in a murine model. Lymphokine Cytokine Res 10:185, 1991.
43. Areman EM, Mazumder A, Kotula PL, Verma UN, Rajagopal C, Hancock S, Guevarra C, Djahanmir M, Sacher RA, Meehan KR: Hematopoietic potential of IL-2-cultured peripheral blood stem cells from breast cancer patients. Bone Marrow Transplant 18:521, 1996.
44. Klingemann HG, Deal H, Reid D, Eaves CJ: Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts. Exp Hematol 21:1263, 1993.
45. Estrov Z, Roifman C, Mills G, Grunberger T, Gelfand EW, Freedman MH: The regulatory role of interleukin 2-responsive T-lymphocytes on human marrow granulopoiesis. Blood 69:1161, 1987.
46. Heslop HE, Duncombe AS, Reittie JE, Bello-Fernandez C, Gottlieb DJ, Prentice HG, Hoffbrand AV, Brenner MK: Interleukin-2 infusion after autologous bone marrow transplantation enhances hemopoietic regeneration. Transplant Proc 23:1704, 1991.
47. Murphy WJ, Keller JR, Harrison CL, Young HA, Longo DL: Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood 80:670, 1992
48. Leclercq G, Debacker V, de Smedt M, Plum J: Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential t/natural killer progenitor cells. J Exp Med 184:325, 1996.
49. Reya T, Contractor NV, Couzens MS, Wasik MA, Emerson SG, Carding SR: Abnormal myelocytic cell development in interleukin-2 (IL-2)-deficient mice: evidence for the involvement of IL-2 in myelopoiesis. Blood 91:2935, 1998.
50. Kuhr T, Bechter O, Geley S, Dietrich H, Dirnhofer S, Eisterer W, Url M, Hilbe W, Lukas P, Thaler J: Autologous transplantation of interleukin-2 gene transduced bone marrow in a preclinical model. J Hematother 26:772, 1998.